Healthcare >> CEO Interviews >> March 30, 2023
Keith Murphy is Founder and Executive Chairman of Organovo Holdings Inc., as well as the CEO and Chairman of Viscient Bio, Inc. He is also a serial entrepreneur and investor in biotech. He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and pharma corporate partnerships. Mr. Murphy spent 10 years at Amgen, including four years as the Global Operations Leader for Prolia and Xgeva. He holds a B.S. in Chemical Engineering from MIT and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves as Board Co-Chair for No Patient Left Behind and on the Board of California Life Sciences. Profile
Word count: 4,517
TWST: To start things off, Keith, could you tell us, what is 3D bioprinting? Is it similar at all to other 3D printing processes?